<h2 dir="ltr">Malignant Pleural Mesothelioma</h2>
Malignant Pleural Mesothelioma (MPM) is a rare and aggressive cancer that develops in the lining of the lungs (pleura), most often caused by prolonged asbestos exposure. It typically presents with symptoms like chest pain, shortness of breath, and fluid buildup around the lungs. MPM has a poor prognosis due to its late diagnosis and limited treatment options, which may include surgery, chemotherapy, radiation, and emerging immunotherapies. Early detection and multidisciplinary care are key to improving outcomes.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Incident Cases of Malignant Pleural Mesothelioma&nbsp;
</li>
<li dir="ltr" aria-level="1">
Gender-Specific Incident Cases of Malignant Pleural Mesothelioma&nbsp;
</li>
<li dir="ltr" aria-level="1">
Age-Specific Incident Cases of Malignant Pleural Mesothelioma&nbsp;
</li>
<li dir="ltr" aria-level="1">
Histology-Specific Incident Cases of Malignant Pleural Mesothelioma&nbsp;
</li>
<li dir="ltr" aria-level="1">
Stage-specific Incident Cases of Malignant Pleural Mesothelioma
</li>
<li dir="ltr" aria-level="1">
Line-wise Treated Cases of Malignant Pleural Mesothelioma
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-epidemiology-forecast">Malignant Pleural Mesothelioma Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, there were 11.4K mesothelioma cases in the 7MM, expected to decline by 2034 at a CAGR of -0.3%.
</li>
<li dir="ltr" aria-level="1">
The U.S. reported ~2,250 cases, accounting for 20% of the 7MM total.
</li>
<li dir="ltr" aria-level="1">
In the EU4 and UK, ~5K cases occurred in males vs. 1.4K in females, showing a clear gender gap.
</li>
<li dir="ltr" aria-level="1">
The UK saw ~1K cases in the 70&ndash;79 age group, representing 43% of age-specific incidence and underscoring the link between age and disease.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market">Malignant Pleural Mesothelioma Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
According to DelveInsight, the Malignant Pleural Mesothelioma market in the 7MM was valued at ~USD 210 million in 2024, projected to grow at a CAGR of 0.7% through 2034.
</li>
<li dir="ltr" aria-level="1">
The U.S. contributed ~48% of the total market.
</li>
<li dir="ltr" aria-level="1">
OPDIVO + YERVOY led among current therapies, generating ~USD 140 million in 2024 across the 7MM.
</li>
</ul>
<h3 dir="ltr">Malignant Pleural Mesothelioma Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Despite global efforts to regulate or ban asbestos use, many developing countries still use asbestos in construction and manufacturing. Due to the long latency period (20&ndash;50 years) between asbestos exposure and disease onset, cases of MPM are expected to continue rising, particularly in regions with historic or ongoing industrial exposure. This persistent burden is driving demand for early diagnosis and new treatment approaches.
</li>
<li dir="ltr" aria-level="1">
The approval of immune checkpoint inhibitors (e.g., nivolumab + ipilimumab) and ongoing trials involving novel agents such as CAR-T therapies, tumor vaccines, and anti-mesothelin antibodies are transforming the treatment landscape. These innovations offer survival benefits over conventional chemotherapy and are creating renewed investment and clinical interest in the MPM space
</li>
</ul>
<h3 dir="ltr">Malignant Pleural Mesothelioma Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
MPM is often diagnosed at an advanced stage due to non-specific symptoms and lack of effective screening tools. This limits treatment eligibility and contributes to poor survival outcomes (median survival: 9&ndash;17 months). Delayed diagnosis significantly curtails the impact of available therapies, posing a challenge to both clinicians and developers.
</li>
<li dir="ltr" aria-level="1">
Advanced therapies like immunotherapies and precision medicine come with high treatment costs, limiting accessibility, especially in regions with underdeveloped healthcare infrastructure. Additionally, the rarity of MPM makes it economically unattractive for some pharmaceutical companies to invest in large-scale trials or regional expansion, further constraining market growth.
</li>
</ul>
<h3 dir="ltr">Malignant Pleural Mesothelioma Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
Volrustomig (MEDI5752)
</li>
<li dir="ltr" aria-level="1">
Pegargiminase with Pemetrexed and Cisplatin
</li>
<li dir="ltr" aria-level="1">
MesoPher
</li>
<li dir="ltr" aria-level="1">
Thiostrepton (RSO-021)
</li>
<li dir="ltr" aria-level="1">
Galinpepimut-S
</li>
<li dir="ltr" aria-level="1">
CTX131
</li>
<li dir="ltr" aria-level="1">
VT3888
</li>
<li dir="ltr" aria-level="1">
NUC-3373
</li>
<li dir="ltr" aria-level="1">
A2B694
</li>
<li dir="ltr" aria-level="1">
TNG462
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight">Malignant Pleural Mesothelioma Key Players</a></h3>
<ul>
<li dir="ltr" aria-level="1">
AstraZeneca
</li>
<li dir="ltr" aria-level="1">
Polaris Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Amphera BV
</li>
<li dir="ltr" aria-level="1">
RS Oncology
</li>
<li dir="ltr" aria-level="1">
Sellas Life Sciences Group
</li>
<li dir="ltr" aria-level="1">
CRISPR Therapeutics AG
</li>
<li dir="ltr" aria-level="1">
Vivace Therapeutics
</li>
<li dir="ltr" aria-level="1">
NuCana plc
</li>
<li dir="ltr" aria-level="1">
A2 Biotherapeutics
</li>
<li dir="ltr" aria-level="1">
Tango Therapeutics
</li>
</ul>
And others.

Malignant Pleural Mesothelioma Market

Malignant Pleural Mesothelioma Market Infographics 

Malignant Pleural Mesothelioma Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.